{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:16:06Z","timestamp":1740107766439,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the National Cancer Center Research and Development Fund","award":["26-A-4","29-A-3"],"award-info":[{"award-number":["26-A-4","29-A-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10147-020-01800-z","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T03:02:53Z","timestamp":1603854173000},"page":"429-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1848-2760","authenticated-orcid":false,"given":"Kenichi","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"1800_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol 17:1244\u20131244","journal-title":"J Clin Oncol"},{"key":"1800_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"1800_CR3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification. J Clin Oncol 32:3059\u20133067","journal-title":"J Clin Oncol"},{"key":"1800_CR4","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489\u20132496","journal-title":"Blood"},{"key":"1800_CR5","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377:2545\u20132554","journal-title":"N Engl J Med"},{"key":"1800_CR6","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Goy A, Offner FC et al (2015) Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-Hodgkin lymphoma: final analysis of the GAUSS Study. J Clin Oncol 33:3467\u20133474","journal-title":"J Clin Oncol"},{"key":"1800_CR7","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Le Gouill S, Feugier P et al (2019) Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol 6:e429\u2013e437","journal-title":"Lancet Haematol"},{"key":"1800_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1800_CR9","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1200\/JCO.2011.34.8508","volume":"29","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, Tobinai K, Shibata T et al (2011) Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin\u2019s lymphoma: JCOG 0203 trial. J Clin Oncol 29:3990\u20133998","journal-title":"J Clin Oncol"},{"key":"1800_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S2352-3026(18)30155-8","volume":"5","author":"T Watanabe","year":"2018","unstructured":"Watanabe T, Tobinai K, Wakabayashi M et al (2018) Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol 5:520\u2013531","journal-title":"Lancet Haematol"},{"key":"1800_CR11","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T et al (2011) Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"1800_CR12","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A et al (2012) Impact of [18F] fluorodeoxyglucose Positron emission tomography response evaluation in patients with high\u2013tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol 30:4317\u20134322","journal-title":"J Clin Oncol"},{"key":"1800_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/10428190601078126","volume":"48","author":"S Assouline","year":"2007","unstructured":"Assouline S, Meyer RM, Infante-Rivard C et al (2007) Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leuk Lymphoma 48:513\u2013520","journal-title":"Leuk Lymphoma"},{"key":"1800_CR14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hidden P, Coiffier B et al (2017) International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 28:1436\u20131447","journal-title":"Ann Oncol"},{"key":"1800_CR15","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541\u20133543","journal-title":"J Clin Oncol"},{"key":"1800_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morchhauser","year":"2018","unstructured":"Morchhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. New Engl J Med 379:934\u2013947","journal-title":"New Engl J Med"},{"key":"1800_CR17","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41375-018-0282-y","volume":"33","author":"R Houotr","year":"2019","unstructured":"Houotr R, Cartron G, Bijou F et al (2019) Obinutuzumab plus lenalidomide (GALEN) for the treatment of relapse\/refractory aggressive lymphoma: a phase II LYSA study. Leukemia 33:776\u2013780","journal-title":"Leukemia"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-020-01800-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T18:04:59Z","timestamp":1611252299000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-020-01800-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1800"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01800-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"2 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KM: No conflicts to disclose. TW: Received honoraria from Bristol-Meyers Squibb, AstraZeneca Pharmaceutical, and Chugai Pharmaceutical, received funding resources from Takara Bio Inc, United Immunity, Co., Ltd., and BrightPath Biotherapeutics Co., Ltd. MW: No conflicts to disclose. KN: No conflicts to disclose. YW: No conflicts to disclose. DM: Received patent licensing fees from Mundi Pharma, Janssen Pharmaceutical, Chugai Pharmaceutical, Eisai, received research funding from Mundi Pharma, Janssen Pharmaceutical, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Celgene, AbbVie. KT: Advisory role of Mundi Pharma, Zenyaku Kogyo, HUYA Bioscience International, Daiichi Sankyo, Ono Pharmaceutical, Takeda Pharmaceutical, received honoraria from Mundi Pharma, Zenyaku Kogyo, HUYA Bioscience International, Eisai, Kyowa Kirin, Ono Pharmaceutical, Takeda Pharmaceutical, Celgene, and Chugai Pharmaceutical, received research funding from Mundi Pharma, Kyowa Kirin, Janssen Pharmaceutical, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Celgene, Takeda Pharmaceutical, AbbVie. KT: Advisory role of HUYA Bioscience International, Daiichi Sankyo, Ono Pharmaceutical, received honoraria from Mundi Pharma, Eisai, Kyowa Kirin, Bayer, Takeda Pharmaceutical, Celgene, and Chugai Pharmaceutical, received research funding from Daiichi Sankyo, HUYA Bioscience International, Chugai Pharmaceutical, Eisai, Bayer, Celgene. HF: No conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}